2011年のものから年次昇順で掲載しています。（最新論文は最後尾 ）　　※2010年以前のものはこちら

326.
L. Levati, F. Ruffini, A. Muzi, K. Umezawa, G. Graziani, S. D'Atri, P. M. Lacal: Placenta growth factor induces melanoma resistance to temozolomide through a mechanism that involves the activation of the transcription factor NF-κB. International J. Oncol. 38: 241-247, 2011.

327.
K. Mino, M. Ozaki, K. Nakanishi, S. Haga, M. Sato, M. Kina, M. Takahashi, N. Takahashi, A. Kataoka, K. Yanagihara, T. Ochiya, T. Kamiyama, K. Umezawa and S. Todo: Inhibition of nuclear factor-kappaB suppresses peritoneal dissemination of gastric cancer by blocking cancer cell adhesion. Cancer Science 102: 1052-1058, 2011.

328.
K. Kobayashi, K. Umezawa and M. Yasui: Apoptosis in mouse amniotic epithelium is induced by activated macrophages through the TNF receptor type 1/TNF pathway. Biology of Reproduction 84: 248-254, 2011.

329.
梅澤一夫、須貝 威：新しいNF-κB阻害剤DHMEQの生物有機化学と抗炎症・抗がん剤への展望。化学と生物　49: 406-414, 2011.

330.
Y. Niitsu, M. Hakamata, Y. Goto, T. Higashi, M. Shoji, T. Sugai and K. Umezawa: Chemoenzymatic synthesis of (2R,3R,4R)-dehydroxymethylepoxyquinomicin (DHMEQ), a new activator of antioxidant transcription factor Nrf2. Org. Biomol. Chem. 9: 4635-4641, 2011.

331.
K. Umezawa: Possible role of peritoneal NF-κB in peripheral inflammation and cancer: Lessons from the inhibitor DHMEQ. Biomedicine & Pharmacotherapy 65: 252-259, 2011.

332.
H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Synthesis and determination of the relative structure of akaterpin, a potent inhibitor of PI-PLC. Tetrahedron Letters 52: 4961-4964, 2011.

333.
V. Rapozzi, K. Umezawa and L. E. Xodo: Role of NF-κB/Snail/RKIP loop in the response of tumor cells to photodynamic therapy. Lasers in Surgery and Medicine 43: 575-585, 2011.

334.
M. Isshiki, K. Umezawa and H. Tamura: Coffee induces breast cancer resistance protein expression in Caco-2 cells. Biol. Pharm. Bull. 34: 1624-1627, 2011.

335.
E. Suzuki, S. Yamashita and K. Umezawa: Role of NF-κB in thyroid cancer. In A. Carpi and J. L. Mechanick eds. “Thyroid Cancer, from Emergent Biotechnologies to Clinical Practice Guidelines” CRC Press, pp 319-327, 2011.

336.
T. Saitoh, M. Takeiri, Y. Gotoh, Y. Ishikawa, K. Umezawa and S. Nishiyama: Design and synthesis of biotinylated DHMEQ for direct identification of its target NF-κB components. Bioorganic & Medicinal Chemistry Letters 21: 6293-6296, 2011.

337.
K. Tsumura, A. Suzuki, T. Tsuzuki, H. Kaneko, S. Matsumura, M. Imoto, K. Umezawa, D. Takahashi and K. Toshima: Molecular design, chemical synthesis, and biological evaluation of agents that selectively photo-degrade the transcription factor estrogen receptor-α. Org. Biomol. Chem. 9: 6357-6366, 2011.

338.
M. Takeiri, M. Tachibana, A. Kaneda, A. Ito, Y. Ishikawa, S. Nishiyama, R. Goto, K. Yamashita, S. Shibasaki, G. Hirokata, M. Ozaki, S. Todo and K. Umezawa: Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Inflammation Research 60: 879-888, 2011.

339.
T. Kubota and K. Umezawa: Suppression of erosive arthritis by NF-κB Inhibitors. Current Rheumatology Reviews 7: 275-281, 2011.

340.
E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. Bioorganic & Medicinal Chemistry Letters 22:164-167, 2012.

341.
T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa, H. Kataoka: Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule inhibitor of nuclear factor-κB, on glioblastoma. Neuro-Oncology 14: 19-28, 2012.

342.
H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. Chem. Pharm. Bull. 60:137-143, 2012

343.
T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N. Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and Satoru Todo: A novel NF-κB inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. Journal of Crohn's and Colotis, in press.

344.
C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S. Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via NFκB pathway on advanced-stage epithelial ovarian cancer. Oncogene, in press.

345.
梅澤一夫：細胞内シグナル伝達分子と創薬。新しい薬学事典　印刷中。

346.
M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K. Miyazono: TGF-β-induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW 264.7 macrophage cells. J. Biochem., in press.

347.
R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I. Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. Endocrinology, in press.

348.
J. A. McCubrey, S. L. Abrams, K. Umezawa, L. Cocco, A. M. Martelli, R. A. Franklin, W. H. Chappell, L. S. Steelman: Novel approaches to target cancer initiating cells-Eliminating the root of the cancer. Advances in Enzyme Regulation, in press.

349.
R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R. Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki, and S. Todo: The immunomodulatory effect of nuclear factor-κB inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. Transplantation, in press.

350.
M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa: Structure-activity relationship 0f 9-methylstreptimidone that induces selective apoptosis in adult T-cell leukemia cells. Oncology Res., in press.

351.
M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K. Umezawa: Involvement of DNA binding domain in the cellular stability and importin affinity of NF- B component RelB. Org. Biomol. Chem., in press.

352.
N. Lampiasi, A. Azzolina1, K Umezawa, G. Montalto, J. A. McCubrey and M. Cervello: The novel NF-kB inhibitor DHMEQ synergizes with Celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett., in press.

353.
A. M. Castro-Gamero, K. S. Borgesa, V. da Silva Silveira, R. C. P. Lira, R. de Paula G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of nuclear factor-jB by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. Anti-Cancer Drugs, in press.

354.
K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa, M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. T and N. Gotoh: ErbB/NFκB signaling controls self-renewal of breast cancer stem cells. Proc. Natl. Acad. Sci. USA, in press.